loading
Schlusskurs vom Vortag:
$7.02
Offen:
$7.03
24-Stunden-Volumen:
8,893
Relative Volume:
0.06
Marktkapitalisierung:
$313.50M
Einnahmen:
$239.40M
Nettoeinkommen (Verlust:
$104.44M
KGV:
2.3345
EPS:
2.96
Netto-Cashflow:
$-18.50M
1W Leistung:
-1.12%
1M Leistung:
-8.57%
6M Leistung:
-59.56%
1J Leistung:
-50.32%
1-Tages-Spanne:
Value
$6.935
$7.075
1-Wochen-Bereich:
Value
$6.80
$7.20
52-Wochen-Spanne:
Value
$6.80
$21.79

Entrada Therapeutics Inc Stock (TRDA) Company Profile

Name
Firmenname
Entrada Therapeutics Inc
Name
Telefon
857-305-1825
Name
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Name
Mitarbeiter
183
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-12
Name
Neueste SEC-Einreichungen
Name
TRDA's Discussions on Twitter

Vergleichen Sie TRDA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TRDA
Entrada Therapeutics Inc
6.98 313.50M 239.40M 104.44M -18.50M 2.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.93 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
528.70 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
317.39 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
563.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.81 28.51B 3.81B -644.79M -669.77M -6.24

Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-06 Eingeleitet ROTH MKM Buy
2024-01-05 Eingeleitet Oppenheimer Outperform
2023-04-03 Eingeleitet H.C. Wainwright Buy

Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten

pulisher
Jun 17, 2025

(TRDA) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 17, 2025
pulisher
Jun 16, 2025

Harbor Capital Advisors Inc. Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Jun 16, 2025
pulisher
Jun 14, 2025

Wall Street Zen Downgrades Entrada Therapeutics (NASDAQ:TRDA) to Sell - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 21,594 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Millennium Management LLC Sells 98,416 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Entrada Therapeutics Holds Virtual Annual Stockholders Meeting - TipRanks

Jun 11, 2025
pulisher
Jun 10, 2025

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Holdings Raised by Bank of America Corp DE - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Entrada Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener

Jun 09, 2025
pulisher
Jun 06, 2025

Mackenzie Financial Corp Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

How the (TRDA) price action is used to our Advantage - news.stocktradersdaily.com

Jun 05, 2025
pulisher
Jun 04, 2025

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLC - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Entrada Therapeutics expands board with new director By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 03, 2025

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Entrada Therapeutics expands board with new director - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Entrada Therapeutics (TRDA) Welcomes New Board Member | TRDA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Entrada Therapeutics Appoints New Board Member - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

3,324 Shares in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Bought by BNP Paribas Financial Markets - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Buys 2,517 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - MarketScreener

Jun 02, 2025
pulisher
Jun 02, 2025

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Entrada Therapeutics Awards Nearly 24,000 RSUs in Latest Employee Compensation Plan - Stock Titan

Jun 02, 2025
pulisher
May 31, 2025

Deutsche Bank AG Grows Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

May 31, 2025
pulisher
May 29, 2025

Entrada Therapeutics to start DMD trial in Q3 2025 By Investing.com - Investing.com South Africa

May 29, 2025
pulisher
May 28, 2025

Entrada Therapeutics (TRDA) Gains EU Approval for Advanced Clinical Study | TRDA Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Entrada Therapeutics to start DMD trial in Q3 2025 - Investing.com

May 28, 2025
pulisher
May 28, 2025

Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025 - Nasdaq

May 28, 2025
pulisher
May 28, 2025

Breakthrough DMD Treatment Gets EU Green Light: Entrada's Novel Exon 45 Therapy Heads to Clinical Trials - Stock Titan

May 28, 2025
pulisher
May 23, 2025

HC Wainwright Brokers Boost Earnings Estimates for TRDA - Defense World

May 23, 2025
pulisher
May 22, 2025

Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace

May 22, 2025
pulisher
May 22, 2025

Q2 Earnings Forecast for TRDA Issued By HC Wainwright - Defense World

May 22, 2025
pulisher
May 22, 2025

HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA) - Defense World

May 22, 2025
pulisher
May 21, 2025

Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

May 21, 2025
pulisher
May 20, 2025

Entrada Therapeutics (TRDA) Receives 'Buy' Rating Reiteration by HC Wainwright | TRDA Stock News - GuruFocus

May 20, 2025
pulisher
May 17, 2025

Tower Research Capital LLC TRC Cuts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

May 17, 2025
pulisher
May 15, 2025

(TRDA) Technical Pivots with Risk Controls - news.stocktradersdaily.com

May 15, 2025
pulisher
May 15, 2025

Roth Capital Issues Negative Outlook for TRDA Earnings - Defense World

May 15, 2025
pulisher
May 14, 2025

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LP - Defense World

May 14, 2025
pulisher
May 12, 2025

Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital - TipRanks

May 12, 2025
pulisher
May 12, 2025

Entrada Therapeutics (TRDA) Sees Price Target Adjustment Amid Cl - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Roth Capital Adjusts Price Target for Entrada Therapeutics (TRDA - GuruFocus

May 12, 2025
pulisher
May 11, 2025

Roth Capital Adjusts Price Target for Entrada Therapeutics (TRDA) | TRDA Stock News - GuruFocus

May 11, 2025
pulisher
May 11, 2025

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results - Yahoo Finance

May 11, 2025
pulisher
May 08, 2025

Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating - TipRanks

May 08, 2025
pulisher
May 08, 2025

Entrada Therapeutics reports Q1 EPS (42c), consensus (77c) - TipRanks

May 08, 2025
pulisher
May 08, 2025

Entrada Therapeutics earnings beat by $0.31, revenue fell short of estimates - Investing.com

May 08, 2025
pulisher
May 08, 2025

Entrada Therapeutics (TRDA) Reports Strong Q1 Revenue and Advances Duchenne Programs | TRDA Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Entrada Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times

May 08, 2025
pulisher
May 08, 2025

First Trust Advisors LP Sells 7,800 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

May 08, 2025
pulisher
May 08, 2025

MetLife Investment Management LLC Acquires 1,731 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

May 08, 2025

Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Entrada Therapeutics Inc-Aktie (TRDA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
WENTWORTH KORY JAMES
Chief Financial Officer
Mar 17 '25
Sale
10.67
1,784
19,035
109,536
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
Kapitalisierung:     |  Volumen (24h):